Cramer’s Mad Cash Recap: House Depot, Moderna, Pfizer

Don’t be too complacent about your negativity, Jim Cramer told his Mad Money viewers on Tuesday. Cramer said his bullish stance remained intact, although Tuesday’s news proved things are a little less positive than they were on Monday.

The day started with what seemed like bad news from Home Depot (HD) – Get the reportwhere sales in the same store turned out to be weaker than expected. The retailer said it was seeing a slowdown in consumer demand, news that had stocks propelled 4.2% by the close of trading.

Home Depot gains were followed by weak retail sales in July, which plummeted 1.1%. On top of that, auto sales are slowing, and Cramer said it was clear our economic expansion could take a break.

Over for real money, Cramer cuts through Home Depot’s reaction: “We just got hit by a two-by-four, but in your stupor don’t confuse this retailer’s report with the whole market and economy,” he writes. Read his assessment of current market developments because, as he says, “someone has to be and I can be”.

Cramer reminded viewers that while Home Depot’s sales during the height of the pandemic did not match those of a year ago, the company was still meeting its sales and earnings numbers. Cramer added that the money never leaves the stock exchange casino, it just goes to other tables. Hence Moderna shares (MRNA) – Get the report and Pfizer (PFE) – Get the report both recovered 7.4% and 3%, respectively. That is also the reason why we have seen increases in everything at Regeneron (RAIN) – Get the report to Dominos Pizza (DPZ) – Get the reportwhen investors switched back to the pandemic winners.

Cramer and the AAP team are reviewing everything from revenue to politics to the Federal Reserve. Find out what they are saying to their investment club members and join the fun with a free trial subscription to Action Alerts Plus.

Executive decision: Roblox

In his first “Executive Decision” segment, Cramer spoke to David Baszucki, founder and CEO of online gaming company Roblox (RBLX) – Get the reportwho reported on Monday mixed results for the quarter.

Baszucki stated that Roblox has come a long way over the past year. He recalled that the Roblox community was locked away at home a year ago, but today, a year later, the world is opening up again and Roblox is still seeing growth in daily active users. This increase resulted in a 112% increase in revenue over the previous year.

Roblox is about a lot more than just gaming, Baszucki continued. They create digital experiences that can include music, objects, and more. That’s why the Roblox version of the popular musical “In The Heights” is so popular. People can experience the film and the locations with their friends up close.

Baszucki concluded by stating that Roblox has grown over the past 15 years, and while the pandemic has brought their community together like never before, he is excited to see what the next 15 years will bring.

Get more trading strategies and investing insights from contributors for real money.

Browse Jim Cramer’s “Mad Money” trading recommendations with our exclusive “Mad Money” stock screener.

To watch reruns of Cramer’s video segments, visit Mad Money page on CNBC.

To sign up for Jim Cramer’s free Booyah! Newsletter with all of his latest articles and videos Please click here.

At the time of publication, Cramer’s Action Alerts PLUS had no position in the named holdings.

Moderna says it hasn’t discovered a hyperlink between its shot and coronary heart irritation

A healthcare worker stops during the coronavirus pandemic (COVID-19) in New York on Jan.

Facebook Facebook logo Sign up on Facebook to connect with Mike Segar Reuters

Modern has found no link between its Covid-19 vaccine and rare heart inflammation cases reported in young people who received the vaccination, the company said on Friday.

The Massachusetts-based biotech said it reached the conclusion after “carefully reviewing the safety data previously available for the Moderna COVID-19 vaccine for cases of myocarditis and / or pericarditis”.

“The company will continue to monitor these reports closely and is actively working with public health and regulators to further evaluate this issue,” said a statement.

A spokesman for the Centers for Disease Control and Prevention did not immediately respond to a request for comment.

A CDC advisory panel is holding an emergency meeting on June 18 to resolve rare but unexpectedly high levels Reports of inflammation of the heart in 16 to 24 year olds after receiving the second dose of Pfizer‘s or Moderna’s Covid-19 vaccines.

A CDC official said Thursday that by May 31, the agency had received reports of 275 cases of myocarditis or pericarditis in this age group, up from the 10 to 102 expected cases. The condition includes inflammation of the heart muscle or the lining around it.

“We clearly have an imbalance,” said Dr. Tom Shimabukuro of the CDC’s Immunization Safety Office on Thursday at a meeting of the FDA’s Advisory Committee on Vaccines and Related Biological Products. The group met to discuss safety issues related to the use of Covid-19 Vaccinations for children from 6 months.

The CDC’s vaccine safety group said last month it is studying heart infections in “relatively few” people who have received Covid vaccinations. Officials say they still don’t know if the condition is really related to the vaccines.

Some of the reported cases could be something other than myocarditis or pericarditis upon further investigation, Shimabukuro said Thursday.

Men make up the majority of reported cases and most cases appear to be mild, officials say. Of the 270 people who developed the disease and were discharged, 81% made a full recovery, according to a CDC presentation at Thursday’s meeting. By May 31, 15 people had been hospitalized, three of them in intensive care, the agency said.

Although no link has been found between the vaccines and the disease, health experts say side effects occur rarely once a vaccine or drug is administered to the general population. The US has distributed millions of Covid vaccines which have helped contain new cases and hospital stays across the country.

Detroit mayor rejects preliminary J&J vaccine cargo, calls Pfizer, Moderna ‘one of the best’

Detroit Mayor Mike Duggan turned down an initial allocation of the Johnson & Johnson Covid-19 single vaccine this week, according to the Michigan State Department of Health.

At a news conference Thursday, Duggan confirmed that he had refused to grant J&J vaccines from the state this week, citing sufficient supply of Pfizer and Moderna vaccines to meet demand from eligible residents.

“Johnson & Johnson is a very good vaccine. Moderna and Pfizer are the best. And I’ll do everything I can to make sure the Detroit city residents get the best,” Duggan said at a news conference Thursday.

The FDA on Saturday authorized J & J’s Covid-19 emergency vaccine is the third vaccine approved for distribution in the United States and the only one that requires only one dose.

Clinical trial data shows that J & J’s vaccine provides 66% overall protection against Covid, compared to around 95% for Pfizer and Moderna vaccines. While some have raised concerns about the lower rate of effectiveness of the J&J vaccine, the J&J vaccine is concerned has proven Prevent 100% of virus-related hospitalizations and deaths according to its clinical trial data.

“All vaccines are safe and effective, and I recommend that all vaccines be offered in all communities,” said Dr. Michigan chief medical executive Joneigh Khaldun in a statement to CNBC.

“Also, the Johnson and Johnson vaccine has been studied in a more recent period of time with more easily transmissible variants, so I would not recommend comparing the Pfizer and Moderna studies directly with the Johnson and Johnson studies,” Khaldun said.

At a news conference on Friday, Andy Slavitt, Senior White House Covid Advisor, said Duggan’s comments on the J&J vaccine had been misunderstood.

“We have had a constant dialogue with Mayor Duggan … He is very excited about the Johnson & Johnson vaccine. And I think we want to reiterate the message that the very first vaccine we can take makes perfect sense for all of us is take, “said Slavitt.

In a statement later Friday, Duggan reiterated the effectiveness of the J&J shot in preventing hospitalizations and Covid-related deaths.

“The only reason we decided not to take the first shipment from Johnson & Johnson was because we had the capacity with Moderna and Pfizer to handle the 29,000 first and second dose appointments planned for the coming week which has already brought us very close to our capacity at our current locations, “Duggan said in a statement on Friday.

The J&J allotment, rejected by Duggan, comprised 6,200 doses that were distributed to other local Michigan health departments, according to Bob Wheaton, spokesman for the state health department.

Wheaton said the state doesn’t expect to receive any more J&J vaccines “for a few weeks.”

Duggan said the city will open a new vaccination site for J&J shots if demand from eligible residents exceeds supply of Moderna and Pfizer cans.

“We always planned to distribute Johnson & Johnson as soon as demand warranted it, and we had our distribution plan so we could make it available to our residents as much as Moderna and Pfizer,” Duggan said in Friday’s statement. “By the time the next J&J broadcast arrives, we’ll have our plan to make it available.”

Moderna asks FDA to permit 5 further doses per Covid vaccine vial: Supply

Modern has asked the U.S. Food and Drug Administration for permission to fill its Covid-19 vaccine bottles with up to five additional doses to help clear a manufacturing bottleneck, according to a person familiar with the matter.

The change would allow Moderna to fill 15 cans into vials of the same size, now cleared for 10, which eases the pressure on the manufacturing process known as filling / finishing, said the person who refused to named because the application is not public yet.

The availability of Covid-19 vaccines has caused frustration since their approval in the US in mid-December. While the pace of administration has increased to an average of more than 1 million a day, the limited supply has hampered states’ ability to operate mass vaccination centers. By Friday, the US had distributed 49.2 million doses and 27.9 million administered Centers for Disease Control and Prevention.

“We have problems making these mRNA vaccines,” said Dr. Paul Offit, director of the Vaccine Education Center and a physician at Philadelphia Children’s Hospital. “We have up to 1.2 million doses a day when we need 3 million doses a day.”

The FDA declined to comment and asked questions to the company. Moderna did not immediately respond to a request for comment.

The move of Moderna comes after that Pfizer requested and received a change in emergency approval from the FDA to indicate that the Covid-19 vaccine bottles contain six doses instead of five after pharmacists determined a bonus dose could be extracted with the correct syringes. Pfizer then said it would ship fewer vials to the US, but the same number of doses specified in its contracts.

Moderna vials have also been found to contain a bonus dose, but a policy change is being sought to add volume to the vials.

The bottleneck is not the vials themselves, but the manufacturing capacity to fill the vials. The manufacturing filling / finishing process must be performed under aseptic conditions to ensure contamination does not occur and the capacity is high.

Companies have begun to form manufacturing partnerships that focus on this step in the process to increase production. Novartis said Friday it signed an initial agreement to fill vials for BioNTech, Pfizer’s partner in Europe for the Covid-19 vaccine.

“We expect this to be the first in a series of such agreements.” said Steffen Lang, Head of Novartis Technical Operations.